The innovative treatment Prolia is one of the main components of successful therapy for women with malignant tumors affecting the bones, as well as osteoporosis and other diseases that contribute to the thinning of the bones. The drug belongs to the group of monoclonal antibodies (that is, antibodies that selectively affect certain types of cells, for example, cancer cells).